HSKA 15.19 Heska Corp $HSKA Hit a 52 week high of 15.27

New Post Public Reply Private Reply Replies (0) Message Board

Nov 6, 2014 at 11:18 PM

HSKA 15.19 Heska Corp $HSKA Hit a 52 week high of 15.27 Closing the day 11/06/14 at 15.19 +0.69 +4.76% With a day low of 14.35 and a total volume of 102,622.

HSKA Recent Posts: http://investorshangout.com/Heska-Corp-HSKA-54376/

HSKA Heska Corp Recent Headline News

Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.05 (+0.05), HSKA: 15.19 (+0.69), ACHN: 10.26 (+0.11), AMAG: 34.12 (+0.34)

Heska Announces Investor Day in New York City
PR Newswire - Tue Nov 04, 8:00AM CST
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today announced the Company will conduct an Investor Day, from 9 a.m. to noon (EST) on Friday, November 14, 2014. The event will be at the Nasdaq MarketSite in Times Square, located at One Liberty Plaza, 165 Broadway, in New York City.
HSKA: 15.19 (+0.69)

Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 323.47 (+3.92), HSKA: 15.19 (+0.69), ILMN: 189.87 (+3.50), QGEN: 23.68 (+0.15)

Can the Rally in Heska (HSKA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:06AM CDT
Can the Rally in Heska (HSKA) Shares Continue?
HSKA: 15.19 (+0.69)

Heska Reports 24% Revenue Growth, $0.08 Per Share for the Third Quarter of 2014
PR Newswire - Wed Oct 29, 8:00AM CDT
Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today reported financial results for its third quarter ended September 30, 2014.
HSKA: 15.19 (+0.69)

Heska Signs Distribution Agreement with Henry Schein Animal Health
PR Newswire - Wed Oct 29, 7:45AM CDT
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, announced today a new distribution agreement with Henry Schein Animal Health, the largest companion animal health distribution company in the U.S. Henry Schein Animal Health will market and promote Heska's full line of hematology and chemistry instruments and affiliated consumables, effective immediately.
HSKA: 15.19 (+0.69), HSIC: 130.31 (+8.10)

Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast
PR Newswire - Tue Oct 28, 3:30PM CDT
Heska Corporation (Nasdaq: HSKA) announces the following Webcast:
HSKA: 15.19 (+0.69)

Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:46AM CDT
Repros Therapeutics (RPRX) was a big mover last session, with shares surging almost 17% on the day.
CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), GILD: 106.94 (+0.89), RPRX: 6.45 (+0.03)

Cyclacel Pharmaceuticals (CYCC) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:21AM CDT
Cyclacel Pharmaceuticals, Inc. (CYCC) was a big mover last session, as the company saw its shares rise by over 5% on the day.
HSKA: 15.19 (+0.69), CBM: 23.48 (+0.55), CYCC: 3.15 (-0.05), GILD: 106.94 (+0.89)

Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 2:20PM CDT
Currently, Myriad Genetics (MYGN) is financing 13 Phase III clinical trials with flagship product BracAnalysis CDx in six different indicated patient populations.
MYGN: 34.78 (+0.17), HSKA: 15.19 (+0.69), CBM: 23.48 (+0.55), GILD: 106.94 (+0.89)

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 15.19 (+0.69), GILD: 106.94 (+0.89), ANTH: 1.86 (unch), QGEN: 23.68 (+0.15)

Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:25AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise over 10% on the day.
RNN: 0.70 (-0.02), HSKA: 15.19 (+0.69), CBM: 23.48 (+0.55), GILD: 106.94 (+0.89)

Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
DVAX: 1.59 (+0.04), HSKA: 15.19 (+0.69), GILD: 106.94 (+0.89), ILMN: 189.87 (+3.50)

Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:44AM CDT
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as the company saw its shares rise over 5% on the day.
ALDR: 16.82 (-0.23), CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), ILMN: 189.87 (+3.50)

Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
HSKA: 15.19 (+0.69), GILD: 106.94 (+0.89), AMGN: 160.35 (+1.41), ILMN: 189.87 (+3.50)

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), DNDN: 0.83 (-0.10), ILMN: 189.87 (+3.50)

Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
CYTK: 4.25 (+0.11), CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), ILMN: 189.87 (+3.50)

Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
SYN: 1.42 (-0.08), CBM: 23.48 (+0.55), HSKA: 15.19 (+0.69), ILMN: 189.87 (+3.50)

China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:32AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise more than 7% on the day.
CBPO: 68.98 (+5.71), HSKA: 15.19 (+0.69), CBM: 23.48 (+0.55), GILD: 106.94 (+0.89)

Heska Corp. (HSKA) Stock Research Links

HSKA Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hi3D Unlocks AI 3D Model for Open-Source Innovation

A New Era in 3D Model Accessibility Unless you’ve been hiding under a rock, it’s hard to miss how digital terraforming has shifted gears. With Hi3D V1.0 opening its doors, the playing field's getting a major reshuffle. Or, as they say, the table is being set, and everyone's getting a seat. By letting loose production-validated AI tools, Hi3D is throwing down the...

Unicycive's Stock Plunge: Fraud Suit and FDA Hurdles

Unicycive's Tumultuous Journey Lately, it's been a rocky road for Unicycive Therapeutics, Inc., with their stock free-falling 39.1% in the span of a heartbeat on June 30, 2026. What sparked this nosedive? The FDA kicked back their revised New Drug Application for a kidney disease treatment yet again, spotlighting old manufacturing issues never nipped in the bud. Talk...

NYC's Carriage Horse Ban: A New Era for Urban Welfare

You've got to hand it to New York City—this isn't just another Tuesday twist. The City Council's decision to nix horse-drawn carriages is like throwing a wrench in an antique machine. It's a bold move in a concrete jungle that's constantly wearing new coats. Tradition vs. Welfare: The Crux For years, the idea of horses prancing down NYC streets seemed like a quaint nod...

Basic Invite's Holiday Card Service Offers Saving Time

Getting the Cards Out: Maneuvering the Holiday Hustle Alright, let's dive into the madness that is holiday card season. Could be a logistical nightmare or a nostalgic tradition, depending on your cup of tea. Basic Invite here is trying to cut through the chaos by bumping deadlines and offering some straight-out-the-gate mailing options. If you play your cards right—pun...

D-Wave Investors Face Pressure Ahead of December 15

Investors Eye December 15 Deadline Nothing like a looming deadline to stir up some anxiety among investors, and that's exactly what's going down at D-Wave Quantum Inc. right now. We're talking about the class action lawsuit spearheaded by the firm Robbins Geller Rudman & Dowd LLP. They've sent out a call to arms for investors who suffered significant losses from February...

Celebrating Alexander Trost: A Lifetime of Compassionate Care

A Legendary Career in Palliative Medicine You know, in a world where people glamorize stock flips and flashy earnings, it's refreshing to spotlight good old-fashioned compassion. Enter Dr. Alexander Trost, DNP, FNP-C, ACHPN. This fella has just been honored as a Pinnacle Lifetime Member by The Inner Circle—a nod to his impactful work in palliative medicine. You ever try...

Tigo Energy Faces Class Action Over Revenue Claims

Trouble Brewing for Tigo Energy? Straight from the horse's mouth, we hear about Tigo Energy (NASDAQ: TYGO) getting embroiled in a class action smackdown. Picture it: Tigo fumbles their projections, and boy does it sting. They're caught in the crossfire for allegedly puffing up their revenue expectations tied to a venture with EG4 Electronics—poised to churn out...

Rising Food Safety Stars Honored: A Global Effort

Food Safety Breakthrough: Youth Leads the Charge When it comes to food safety, it’s about time the younger crowd gets their due. The latest crew to step up to the plate is the Class of 2026's 40 Under 40 Food Safety Professionals. They’re not just pushing paper; these folks are setting the bar high and innovating across continents with real, tangible changes. From...

Ellington's Q3 Earnings Call: What Investors Need to Know

An Anticipated Unveiling Ellington Financial Inc. (NYSE:EFC) is gearing up to spill the beans on its third-quarter financials for 2026. It's all going down after the markets close on November 4th. I can tell you, folks, anyone keeping an eye on EFC will be itching to know what's inside those numbers. With a company this deep into financial assets, reading between the...

Dott's Q3 2026: Micromobility Growth Soars High

Riding the Wave of Profit in Micromobility Sometimes all you need is a quick jolt of genius to turn the wheels of fortune. Dott seems to have hit that sweet spot in Q3 of 2026. Deploying 45,000 new vehicles wasn’t just a logistical feat; it was a calculated bet that paid off handsomely, bolstering their business to soaring heights. Performance that Packs a Punch The Q3...